The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
|Videos|May 18, 2011
Dr. Markman Discusses the Swedish PSA Screening
Author(s)Maurie Markman, MD
Dr. Markman Discusses the Swedish PSA Screening
Advertisement
Maurie Markman, MD the National Director for Medical Oncology for the Cancer Treatment Centers of America Discusses the Swedish PSA Screening Study
Advertisement
Related to this article
The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.
Carotuximab plus apalutamide demonstrated longer median progression-free survival than apalutamide alone in an interim phase 2 analysis in mCRPC.
A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
Earlier CAR T-Cell Therapy Use Highlights Sequencing and Access Considerations in Myeloma
2
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
3
CDK4/6 Inhibitors Anchor First-Line Metastatic Breast Cancer Care, But Oral SERDs May Fall Short
4
Real-World, First-Line IO-Based Combos Are Associated With Improved OS vs TKI Monotherapy in Advanced RCC
5